Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377587 | 0.98 | CYP19A1 (0.33) | ALDH1A1L3MBTL1CYP19A1CA2NAAA | |
| SCHEMBL645146 | 0.73 | CYP19A1 (0.36) | CYP19A1SCN1ASCN2ASCN3A | |
| SCHEMBL9052834 | 0.71 | CYP19A1 (0.33) | CYP19A1SCN1ASCN2ASCN3A | |
| SCHEMBL6623048 | 0.69 | CYP2C19 (0.40) | — | |
| SCHEMBL8863 | 0.69 | NPSR1 (0.43) | CYP19A1EPHX2 | |
| SCHEMBL383938 | 0.68 | CYP2C19 (0.35) | — | |
| SCHEMBL1300037 | 0.68 | SCN1A (0.51) | ALDH1A1L3MBTL1CYP19A1NAAASCN1A | |
| SCHEMBL7183801 | 0.67 | NPSR1 (0.39) | ALDH1A1CYP19A1CA2NAAASCN1A | |
| SCHEMBL5677016 | 0.67 | TSHR (0.31) | — | |
| SCHEMBL10922421 | 0.67 | SMN1; SMN2 (0.36) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0048573-B1 | POLYPEPTIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-08-01 | — | — | EP | claimed |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBVIE INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | SERPINB1, PREP, DNPEP | ALDH1A1 3021/4885L3MBTL1 1673/4885CYP19A1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.